Insights

  • Date

  • Content Type

  • Reset

Blog

Risk Management Plans for ATMPs

13.06.21

by Maria Schacker

ATMPs are a relatively novel class of medicinal products with anew and very unique set...

Blog

Neutralizing Antibody Assay Development – a key consideration for immunogenicity packages

01.06.21

by Jennifer Sales

Neutralising Antibodies, or NAbs, are a subclass of Anti-Drug Antibodies that may be formed during...

Blog

Better late than never? What developers of SARS-CoV-2 vaccines in early-to -late-stage development should consider

12.05.21

by Michael Pfleiderer, Ilona Baraniak and Ciaran Greene

Unfortunately, as of today the ongoing pandemic is still far...

Blog

Wake up the Sleeping Beauty – Transposons in gene therapy: How do they compare to other genome modifying tools?

04.05.21

by Ewa Janosz

Gene therapy is currently a quickly developing field. Except from commonly known viral vectors and...

Blog

Requests for proposals – Get the best value when asking for services

26.04.21

by Timo Liebig

You need a service provider, but which one suits your needs best? Read here how...

Blog

AAV gene therapy development: Immunogenicity and safety aspects

02.03.21

by Eveline Molocea and Jörg Schneider

Adeno-associated virus (AAV) is a dominant gene delivery platform that matured in...